Articles related to BENZODIAZEPINES

Sedative-hypnotic drug effects vary with meal timing, metabolism, and drug half-life in patients with insomnia. These pharmacologic factors influence sleep onset and maintenance, particularly in patients with psychiatric comorbidities requiring concurrent medications.

Celebrity disclosures about using beta blockers for performance anxiety are prompting patient questions in primary care, reviving a decades-old off-label use with a comparatively lower risk profile than benzodiazepines.

A J Clin Psychiatry commentary proposes a risk-benefit matrix favoring empiric catatonia treatment when diagnostic uncertainty exists, citing the syndrome’s high morbidity and the effectiveness of available interventions.

Viatris recalled one lot of Xanax XR 3-mg extended-release tablets after failed dissolution testing, with the FDA classifying the action as Class II and reporting no adverse events to date.

Deprescribing benzodiazepines in patients on long-term stable treatment led to increased mortality along with increases in nonfatal overdoses, suicidal ideation, and emergency department visits.